Cber
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
Coverage of Cber is holding steady : 10 signals on the latest tracked day, level with its three-week baseline of 10, across 2 domains.
Cber is steady by its own history. Its normal rhythm is about 10 signals a day across 2 domains. A real move would be a day at 13+ signals — 25% above that baseline, the bar our trend read calls accelerating — or a spread into domains beyond its usual 2. That is the move that would push it up the Wire.
What’s changed
- Recently Issued Guidance Documents · FDA — What's New: Drugs · 2026-09-17
- Investigational New Drug Application (IND) · FDA — What's New: Drugs · 2026-09-17
- C3TI Compass (Knowledge Repository) · FDA — What's New: Drugs · 2026-09-17
- Animal Rule Information · FDA — What's New: Drugs · 2026-09-17
- FDA Launches Expedited IND Pilot, Begins Accepting Applications · FDA — Press Releases · 2026-09-16
- FDA Expedited Investigational New Drug (IND) Pilot Program · FDA — What's New: Drugs · 2026-09-16
What the reporting says
Across 22 tracked stories from 3 outlets, reporting on Cber most often describes regulatory approvals (11), award (1).
It shows up alongside Cder (17), FDA (22), Drug Evaluation (13), Biological Products (11), Drug Development (9), Biologics Evaluation (13), Drug Administration (8).
Two steps out: AI (through FDA, 22 shared stories on the weaker link); China (through FDA, 22 shared stories on the weaker link); Colorectal Cancer (through FDA, 22 shared stories on the weaker link); Trump (through FDA, 22 shared stories on the weaker link).
Tracked since Apr 17, with coverage on 15 separate days — concentrated in Biotech Pharma and Regulatory.